While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients

While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients

Source: 
Endpoints
snippet: 

As a late-stage data showdown from NASH drug developers Gilead $GILD, Intercept $ICPTand France’s Genfit (EuroNext: $GNFT) looms, the Lille-based drug developer on Thursday reported positive phase II data on its drug elafibranor in patients with primary biliary cholangitis (PBC), a rare and progressive liver disease.